Semax (ACTH Fragment Peptide)

Semax, MT-2 and KPV Are Pieces of the Same Sequence

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Alpha-MSH is thirteen residues. Semax retains positions 4 to 7, MT-2 is built around a core corresponding to positions 6 to 9, and KPV is positions 11 to 13 exactly. Three separate product categories on this site are fragments of one sequence.

Key facts

Parent
alpha-MSH, 13 residues, 1,664.9 Da
Semax retains
Positions 4-7, Met-Glu-His-Phe
Semax replaces
Positions 8-10 with Pro-Gly-Pro
MT-2 core
His-D-Phe-Arg-Trp, positions 6-9
KPV
Lys-Pro-Val, positions 11-13
Overlap
Semax and MT-2 share His-Phe (6-7)
KPV
Adjacent and non-overlapping

The parent sequence

Alpha-MSH runs Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val, acetylated at the front and amidated at the end. Numbering those positions one to thirteen is what makes the fragment literature legible. Every compound discussed here is described by which of those positions it keeps.

Where Semax sits

Semax is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues are positions 4 to 7 of the parent. What follows is not the parent's positions 8 to 10 (Arg-Trp-Gly) but Pro-Gly-Pro substituted in their place. So Semax keeps the front of the shared region and discards the part that follows it.

Research material referenced

Semax 10mg, third-party HPLC tested

Buy Semax · £24.99

Where MT-2 sits

MT-2 is a cyclic heptapeptide whose core reads His-D-Phe-Arg-Trp, corresponding to positions 6 to 9, with norleucine standing in for the methionine position and D-phenylalanine replacing the L form. Those four residues are the recognised melanocortin receptor-binding core, which is why a compound built to engage those receptors is built around them.

Where KPV sits

KPV is Lys-Pro-Val, positions 11, 12 and 13, the C-terminal end of the parent, taken unmodified. It is the only one of the three that is an exact excerpt rather than an analogue.

What the map shows

Semax and MT-2 overlap at His-Phe, positions 6 and 7. KPV lies beyond both, adjacent and non-overlapping. The three compounds together cover most of the parent's second half, carved into pieces by three different research programmes pursuing three different questions, cognition, pigmentation and inflammation.

Why the pieces behave so differently

Because what each retains determines what it can do. MT-2 keeps the receptor-binding core and is built to engage melanocortin receptors. KPV keeps the C-terminal tail associated with anti-inflammatory activity and deliberately discards the receptor core. Semax keeps the front of the region and replaces what follows with a stability motif. Same parent, three different design intentions, three different molecules.

The regulatory position across all three

None of Semax, MT-2 or KPV holds a marketing authorisation from the MHRA, EMA or FDA. All are supplied here for laboratory research only, and no claim is made about any of them in relation to any condition in any person.

Quick reference

Compoundalpha-MSH positionsRelationship
Semax4-7 retainedAnalogue (8-10 replaced by Pro-Gly-Pro)
MT-26-9 as coreAnalogue (cyclised, D-Phe, Nle)
KPV11-13Exact excerpt

Frequently asked questions

Do any of them overlap?

Semax and MT-2 share His-Phe at positions 6 and 7. KPV, at positions 11 to 13, is adjacent and does not overlap either.

Why do they behave so differently?

Because what each retains determines what it can do, MT-2 keeps the receptor-binding core, KPV keeps the C-terminal tail and discards that core.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Semax (ACTH Fragment Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.